申请人:Pfizer Inc.
公开号:US04476307A1
公开(公告)日:1984-10-09
Certain substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones are highly potent gabaergic agents, valuable in the treatment of individuals suffering from schizophrenia or reversing the side effects of a previously or concurrently administered neuroleptic agent; or in the treatment of epilepsy. A wider class of substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones, together with 1-phenyl-3-(2-pyrrolidinylidene)-2(1H,3H)-indolones, and homologs thereof, are valuable in the treatment of anxiety.
某些取代的1-苯基-3-(氨基烷基亚甲基)-2(1H,3H)-吲哚酮是高效的GABA能药物,在治疗患有精神分裂症或翻转先前或同时给予的神经精神药物的副作用方面非常有价值;或在治疗癫痫方面也非常有价值。一类更广泛的取代的1-苯基-3-(氨基烷基亚甲基)-2(1H,3H)-吲哚酮,以及1-苯基-3-(2-吡咯烷基亚甲基)-2(1H,3H)-吲哚酮及其同系物,在治疗焦虑方面也非常有价值。